Literature DB >> 20846939

Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients.

Christiaan L Meuwese1, Sunna Snaedal, Nynke Halbesma, Peter Stenvinkel, Friedo W Dekker, Abdul R Qureshi, Peter Barany, Olof Heimburger, Bengt Lindholm, Raymond T Krediet, Els W Boeschoten, Juan J Carrero.   

Abstract

BACKGROUND: The impact of intra-individual changes of inflammatory markers [other than C-reactive protein (CRP)] on mortality in haemodialysis (HD) patients is unknown. We therefore studied survival in relation to trimestral variations of CRP, interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α).
METHODS: In 201 prevalent HD patients from the Mapping of Inflammatory Markers in Chronic Kidney Disease cohort, serum CRP, IL-6 and TNF-α were measured 3 months apart and survival was assessed during follow-up. Based on fluctuations along tertiles of distribution, four patterns were defined for each inflammatory marker: stable low, decrease, increase and stable high. Hazard ratios were calculated by the Cox proportional hazard model, and Pearson's test was used to correlate changes. CRP analyses were replicated in 472 incident HD patients from the Netherlands Cooperative Study on the Adequacy of Dialysis.
RESULTS: Patients with persistently elevated CRP values had the worst mortality in crude [HR 2.98 (95% CI 1.71-5.20)] and adjusted [2.79 (1.58-4.94)] Cox models, together with those who increased in their CRP levels [crude 3.27 (1.91-5.60); adjusted 3.13 (1.79-5.45)]. Similar survival patterns were observed for IL-6 and TNF-α variation categories. Correlations among these changes were, however, not strong. In the replication cohort, individuals with persistently elevated CRP values also showed the highest mortality risk [crude 3.38 (2.31-4.94); adjusted 2.33 (1.58-3.45)].
CONCLUSIONS: Trimestral variations of TNF-α, IL-6, and CRP are similarly associated with survival in HD patients. The agreement between changes of these biomarkers was low, suggesting that different pathways may trigger each of these markers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20846939     DOI: 10.1093/ndt/gfq557

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  34 in total

Review 1.  Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis.

Authors:  Alberto Ortiz; Ziad A Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Carmine Zoccali
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

Review 2.  Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field.

Authors:  Natasha Dave; Jiao Wu; Sandhya Thomas
Journal:  Curr Diab Rep       Date:  2018-06-08       Impact factor: 4.810

3.  Clinical predictors of decline in nutritional parameters over time in ESRD.

Authors:  Claire H den Hoedt; Michiel L Bots; Muriel P C Grooteman; Neelke C van der Weerd; E Lars Penne; Albert H A Mazairac; Renée Levesque; Peter J Blankestijn; Menso J Nubé; Piet M ter Wee; Marinus A van den Dorpel
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

4.  C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Authors:  Wei-Hung Kuo; Yueh-Ting Lee; Hwee-Yeong Ng; Chun-Yeh Wang; Chien-Hsing Wu; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2017-04-27       Impact factor: 2.352

5.  Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients.

Authors:  Christiaan L Meuwese; Friedo W Dekker; Bengt Lindholm; Abdul R Qureshi; Olof Heimburger; Peter Barany; Peter Stenvinkel; Juan J Carrero
Journal:  Clin J Am Soc Nephrol       Date:  2012-01       Impact factor: 8.237

6.  Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival.

Authors:  Mark Lambie; James Chess; Kieron L Donovan; Yong Lim Kim; Jun Young Do; Hi Bahl Lee; Hyunjin Noh; Paul F Williams; Andrew J Williams; Sara Davison; Marc Dorval; Angela Summers; John D Williams; John Bankart; Simon J Davies; Nicholas Topley
Journal:  J Am Soc Nephrol       Date:  2013-09-05       Impact factor: 10.121

Review 7.  Monitoring of inflammation in patients on dialysis: forewarned is forearmed.

Authors:  Christiaan L Meuwese; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2011-03       Impact factor: 28.314

8.  Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD.

Authors:  Belinda Spoto; Francesco Mattace-Raso; Eric Sijbrands; Daniela Leonardis; Alessandra Testa; Anna Pisano; Patrizia Pizzini; Sebastiano Cutrupi; Rosa M Parlongo; Graziella D'Arrigo; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-09       Impact factor: 8.237

Review 9.  Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.

Authors:  Usama Elewa; Maria Dolores Sanchez-Niño; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2012-09-11       Impact factor: 2.370

10.  Dietary fiber, kidney function, inflammation, and mortality risk.

Authors:  Hong Xu; Xiaoyan Huang; Ulf Risérus; Vidya M Krishnamurthy; Tommy Cederholm; Johan Arnlöv; Bengt Lindholm; Per Sjögren; Juan Jesús Carrero
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-03       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.